Nektar Therapeutics
NKTRNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $1.28B
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $33.40$109.00
- Volume (live)
- -
- Avg. volume (3M)
- 1.63M
Nektar Therapeutics (NKTR) Stock Price & Financial Analysis
Nektar Therapeutics Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $37.00 - $38.80 |
|---|---|
| 52-Week High | $109.00 |
| 52-Week Low | $33.40 |
| Open | $38.01 |
| Volume (last close) | 1.02M |
| Average Volume (3M) | 1.63M |
| Revenue (TTM) | 54.59M |
|---|---|
| Net Income (TTM) | -157.13M |
| Free Cash Flow (TTM) | -234.03M |
| EPS (TTM) | −$6.48 |
| Profit Margin | -287.84% |
| Operating Margin | -239.32% |
| Return on Equity (ROE) | -17.40% |
| Debt to Equity | 0.09 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Market Cap | 1.28B |
|---|---|
| Shares Outstanding | 33.05M |
| Price to Sales (P/S) | 23.40 |
| Price to Book (P/B) | 1.41 |
| EV/EBITDA | -9.99 |
| 50-Day MA | $61.51 |
|---|---|
| 200-Day MA | $65.09 |
| 1-Year Change | −39.27% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Nektar Therapeutics at a Glance
As of the Oct 22, 2026 close, Nektar Therapeutics (NKTR) has a market capitalization of $1.28B. The stock trades at 23.4× sales. Over the trailing twelve months it lost $157.13M on revenue of $54.59M and burned $234.03M of free cash flow. Revenue fell 27.1% year over year.
As of its latest reported balance sheet, it holds $39.27M in cash and securities against $78.56M of debt, a net debt position of $39.29M.
Nektar Therapeutics does not currently pay a dividend.
The share price is down 39.3% over the past year. At $38.65 (the Oct 22, 2026 close) it sits near the bottom of its 52-week range of $33.40 to $109.00, below its 200-day moving average of $65.09.
Based on 16 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $132.45, 242.7% above the Oct 22, 2026 close.
Frequently Asked Questions About Nektar Therapeutics
What is the current stock price for NKTR?
As of the Oct 22, 2026 close, NKTR stock trades at $38.65. The 52-week range is $33.40–$109.00, with a day range of $37.00–$38.80.
What is the P/E ratio for NKTR?
The P/E ratio (Price-to-Earnings) for NKTR is shown in the Key Statistics section. This valuation metric helps compare Nektar Therapeutics to industry peers.
Does NKTR pay dividends?
Nektar Therapeutics does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for NKTR?
Based on ratings from 16 professional analysts over the last 90 days, the consensus for NKTR is Buy. The average 12-month price target is $132.45, a 242.7% upside from the Oct 22, 2026 close of $38.65.
What is the market cap of NKTR?
As of the Oct 22, 2026 close, Nektar Therapeutics's market capitalization is $1.28B, classifying it as a small-cap company. Nektar Therapeutics operates in the Healthcare sector within the Biotechnology industry.